Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

CRH hails strong Q2, lifts guidance for 2025

(Sharecast News) - CRH surged on Thursday as the building materials group lifted its guidance for 2025 after posting a jump in second-quarter profit and sales. Adjusted earnings before interest, tax, depreciation and amortisation rose 9% on the same period a year earlier to $2.5bn, with revenue up 6% to $10.2bn. CRH said its performance was underpinned by favourable underlying demand, positive pricing and acquisition contributions.

Net income ticked up 2% to $1.3bn and the group declared a quarterly dividend of $0.37, up 6% on the prior year.

Chief executive Jim Mintern said: "Our strong second quarter performance was driven by favourable underlying demand, disciplined commercial management and further contributions from acquisitions.

"CRH's proven strategy continued to drive higher sales, profits and adjusted EBITDA margins, while our robust balance sheet and financial capacity enabled us to allocate approximately $3 billion to growth investments and capital returns year-to-date."

CRH said it now expects FY net income of $3.8bn to $3.9bn and adjusted EBITDA of $7.5bn to $7.7bn. This compares to previous guidance of $3.7bn to $4.1bn and $7.3m to $7.7m, respectively.

"We continue to expect favourable underlying demand across our key end-use markets in 2025, underpinned by significant public investment in critical infrastructure and continued re-industrialization activity in key non-residential segments," it said.

"Within the residential sector, the new-build segment is expected to remain subdued, while repair and remodel activity remains resilient. Assuming normal seasonal weather patterns and absent any major dislocations in the political or macroeconomic environment, CRH's proven strategy and leading positions of scale in attractive higher-growth markets, together with our strong and flexible balance sheet, are expected to underpin another year of growth and value creation in 2025."

At 0950 BST, the shares were up 6.9% at 7,866p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.